Unintended hepatic adverse events associated with cancer chemotherapy

Toxicologic Pathology

Volumn 38, Issue 1, 2010, Pages 142-147

  Senior, John R ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Benefit risk balance; Chemotherapy; Hepatoxicity; Liver adaptation

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; ISONIAZID; LIVER ENZYME; TROGLITAZONE;

AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FALSE POSITIVE RESULT; HUMAN; LIVER INJURY; LIVER REGENERATION; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TUBERCULOSIS; ARTICLE; BLOOD; DRUG EFFECT; LIVER; NEOPLASM; PATHOLOGY;

ALANINE TRANSAMINASE; ANTINEOPLASTIC AGENTS; HUMANS; LIVER; NEOPLASMS;

EID: 77952294692     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623309351719     Document Type: Review

References (29)

1. Alberg, A. J., Park, J. W., Hager, B. W., Brock, M. V., and Diener-West, M. (2004). The use of "overall accuracy" to evaluate validity of screening or diagnostic tests. J Gen Int Med 19, 460-465
2. Alden, C., Lin, J., and Smith, P. (2003). Predictive toxicology technology for avoiding idiosyncratic liver injury. Preclinica 2, 27-35.
3. Assis, D. N., and Navarro, V. J. (2009). Human drug hepatotoxicity: A contemporary clinical perspective. Expert Opin Drug Metab Toxicol 5, 463-473
4. Atiqi, R., van Iersel, C., and Cleophas, T. J. (2009). Accuracy assessments of quantitative diagnostic tests for clinical research. Int J Clin Pharmacol Ther 47, 153-158
5. Blumgart, L. H., Leach, K. G., and Karran, S. J. (1971). Observations on liver regeneration after right hepatic lobectomy. Gut 12, 922-928
6. Chun, Y. S., Laurent, A., Maru, D., and Vautney, J-N. (2009). Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 10, 278-286
7. Cleophas, T. J., Droogendijk, J., and van Ouwerkerk, B. M. (2008). Validating diagnostic tests, correct and incorrect methods, new developments. Curr Clin Prarmacol 3, 70-76.
8. Córdoba, J., O'Riordan, K., Dupuis, J., Borensztajn, J., and Blei, A. T. (1998). Diurnal variation of serum alanine transaminase activity in chronic liver disease. (Letter) Hepatology 28, 1724-1725
9. Davidson, C. S., Leevy, C. M., and Chamberlayne, E. C. (eds.) (1979). Guidelines for Detection of Hepatotoxicity due to Drugs and Chemicals. [Fogarty Conference, 1978] NIH Publication No. 79-313. US Government Printing Office, Washington, DC, p. 109.
10. Eklund, J. W., Trifilio, S., and Mulcahy, M. F. (2005). Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) 19, 1057-1063
11. Field, K. M., Dow, C., and Michael, M. (2008). Part I: Liver function in oncology: Biochemistry and beyond. Lancet Oncol 9, 1092-1101
12. Field, K. M., and Michael, M. (2008). Part II: Liver function in oncology: Toward safer chemotherapy use. Lancet Oncol 9, 1181-1190
13. Floyd, J., Mirza, I., Sachs, B., and Perry, M. C. (2006). Hepatotoxicity of chemotherapy. Semin Oncol 33, 50-67.
14. Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., and Rochon, J, for the DILIN Study Group. (2009). Drug-induced liver injury network (DILIN) prospective study: Rationale, design, and conduct. Drug Safety 32, 55-68.
15. Graham, D. J., Green, L., Senior, J. R., and Nourjah, P. (2003). Troglitazoneinduced liver failure: A case study. Am J Med 114, 299-306.
16. Kaplan, M. M. (2002). Alanine aminotransferase levels: What's normal? Ann Intern Med 137, 49-51.
17. Karmen, A.,Wroblewski, F., and LaDue, J. S. (1955). Transaminase activity in human blood. J Clin Invest 34, 126-131
18. King, P. D., and Perry, M. C. (1995). Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am 24, 969-990
19. Kopanoff, D. E., Snider, D. E. Jr., and Caras, G. J. (1978). Isoniazid-related hepatitis: A U.S. Public Health Service cooperative surveillance study. Am Rev Resp Dis 117, 991-1001.
20. Lawrence, T. S., Robertson, J. M., Anscher, M. S., Jirtle, R. L., Ensminger,W. D., and Fajardo, L. F. (1995). Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31, 1237-1248
21. Ledley, R. S., and Lusted, L. B. (1959). Reasoning foundations of medical diagnosis: Symbolic logic, probability, and value theory aid our understanding of how physicians reason. Science 130, 9-21.
22. National Cancer Institute. Common Toxicity Criteria for Adverse Events (CTCAE), version 3.0 (2007). Available at: https://webapps.ctep.nci.nih.gov/ webobjs/ctc/webhelp/welcome-to-ctcae.htm. Accessed 13 October 2009.
23. Nolan, C. M., Goldberg, S. V., and Buskin, S. E. (1999). Hepatotoxicity associated with isoniazid preventative therapy: A 7-year survey from a public health tuberculosis clinic. JAMA 281, 1014-1018
24. Prado, C. M. M., Baracos, V. E., McCargar, L. J., Mourtzakis, M., Mulder, K. E., Reiman, T., Butts, C. A., Scarfe, A. G., and Sawyer, M. B. (2007). Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13, 3264-3268
25. Prati, D., Taioli, E., Zanella, A., Della Torre, E., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., Conte, D., Colombo, M., and Sirchia, G. (2002). Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137, 1-10.
26. Senior, J. R. (1999). Drugs and the Liver: What They Do To Each Other. (FDA conference held in at University of Maryland Shady Grove Center). Available at http://www.fda.gov/downloads/ScienceResearch/ResearchAreas/ucm072996.pdf. Accessed 13 October 2009.
27. Senior, J. R. (2003). Healthy ranges for alanine aminotransferase levels. Ann Intern Med 138, 156-157
28. Senior, J. R., and Avigan, M. I. (2008). Classification system for likelihood and severity of drug-induced liver injury to score clinical importance of the case. (Abstract #445 and poster, AASLD annual meeting, San Francisco CA, 1 Nov 2008). Hepatology 48, 506A-507A.
29. Temple, R. (2006). Hy's law: Predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 15, 241-243